Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kalbe Farma TbkFRA:LCLA 77 Debt-to-EBITDA is 0.05 as of Mar. 2026, which is 62% below its 10-year median of 0.13. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.10 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 90.43% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Kalbe Farma Tbk's Debt-to-EBITDA or its related term are showing as below:
FRA:LCLA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06 Med: 0.13 Max: 0.29
Current: 0.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of PT Kalbe Farma Tbk was 0.29. The lowest was 0.06. And the median was 0.13.
FRA:LCLA's Debt-to-EBITDA is ranked better than 90.43% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs FRA:LCLA: 0.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Kalbe Farma Tbk Debt-to-EBITDA Related Terms
PT Kalbe Farma Tbk Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
PT Kalbe Farma Tbk (FRA:LCLA) has a Debt-to-EBITDA of 0.05 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Kalbe Farma Tbk. This is 62% below median its historical median of 0.13. Over the past decade, PT Kalbe Farma Tbk's Debt-to-EBITDA has ranged from 0.06 to 0.29. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #66 out of 690 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is PT Kalbe Farma Tbk's Debt-to-EBITDA too high?
PT Kalbe Farma Tbk's current Debt-to-EBITDA of 0.05 is 62% below median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.29. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. PT Kalbe Farma Tbk's value of 0.05 is 97% below this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #66 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #66 out of 690 companies for Debt-to-EBITDA. This places PT Kalbe Farma Tbk in the top 10% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. PT Kalbe Farma Tbk's value of 0.05 is 97% below this benchmark. Historically, PT Kalbe Farma Tbk's own Debt-to-EBITDA has ranged from 0.06 to 0.29 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 1.64, PT Kalbe Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current Debt-to-EBITDA of 0.05 is 97% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Kalbe Farma Tbk. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current Debt-to-EBITDA is 0.05, which is 62% below median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.03 — trading 70% below its estimated fair value. The current Debt-to-EBITDA is 0.05, which is 62% below median its 10-year median of 0.13 and 97% below the Drug Manufacturers industry median of 1.64. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Debt-to-EBITDA is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 70% below its estimated GF Value™ of €0.10.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
Debt-to-EBITDA: 0.05 (62% below median its 10-year median of 0.13)
GF Value™: €0.10 vs. price of €0.03 (70% below fair value)
Industry Position: 97% below the Drug Manufacturers median (#66 of 690)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
